Covid Vaccines Have Paved the Way for Cancer Vaccines
If you buy something using links in our stories, we may earn a commission. This helps support our journalism. Learn more. Please also consider subscribing to WIRED
Lennard Lee, a UK National Health Service oncologist and medical director at the Ellison Institute of Technology in Oxford, calls himself just a 'simple doctor,' but he's anything but. During the pandemic, he led clinical efforts that showed it was still safe to give cancer patients chemotherapy, disproving fears that the coronavirus made this too risky, helping to maintain cancer treatment worldwide. He also delivered UK research that showed lateral flow testing was effective in identifying the most infectious Covid patients.
His most important project, however, is the one he's currently leading as the national government advisor for mRNA cancer vaccines. This new type of vaccine, which is based on the same technology as the Covid vaccines first developed by BioNTech and Moderna, is seen by many as a potential breakthrough in the fight against cancer. Ahead of speaking at WIRED Health in London next week, Lee tells WIRED why he hopes these vaccines will prove to be the 'silver lining of the pandemic.'
This interview has been edited for length and clarity.
WIRED: There are currently hundreds of mRNA cancer vaccine trials ongoing worldwide. How did the success of mRNA Covid vaccines kickstart this?
Lennard Lee: Cancer vaccines weren't a proper field of research before the pandemic. There was nothing. Apart from one exception, pretty much every clinical trial had failed. With the pandemic, however, we proved that mRNA vaccines were possible.
WIRED Health showcases the most exciting and thought-provoking disruptors, scientists, and practitioners making a positive change in how we provide and access health care. Find out more.
mRNA cancer vaccines work by giving the body instructions to make a harmless piece of a cancer-related protein. This trains the immune system to recognize and attack cancer cells carrying that protein. Think of it like a training manual for security guards. The vaccine gives the immune system a guide on what cancer looks like, so it knows exactly who to watch for and remove.
Going from mRNA Covid vaccines to mRNA cancer vaccines is straightforward: same fridges, same protocol, same drug, just a different patient.
In the current trials, we do a biopsy of the patient, sequence the tissue, send it to the pharmaceutical company, and they design a personalized vaccine that's bespoke to that patient's cancer. That vaccine is not suitable for anyone else. It's like science fiction.
In the UK, you set up the Cancer Vaccine Launch Pad at the end of 2022 to fast-track cancer vaccine trials. Why set up such an ambitious project right after the Covid pandemic?
The pandemic was ending, the Omicron variant was much milder than previous variants, and everyone had had their vaccines. Research in the area of Covid vaccines was starting to close down, but companies like Moderna and BioNTech were trying to figure out what to do next, because there wasn't going to be a need for a Covid vaccine market forever. So they started to pivot to cancer vaccines using mRNA technology, and they were looking for countries with proven capabilities for vaccine research and manufacture.
In the meantime, the UK was ready. We had fridges and we had world-class manufacturing and research facilities. During the pandemic, we had proven we could open and deliver clinical trials fast. Also, the UK had established a genomic global lead with Genomics England and the 100,000 Genome Project. All doctors and nurses in this country are trained in genomics. That was a big signpost for any pharmaceutical industry.
So the UK government signed two partnerships: one with BioNTech to provide 10,000 patients with access to personalized cancer treatments by 2030, and a 10-year investment with Moderna in an innovation and technology center with capacity to produce up to 250 million vaccines. The stars were aligned.
During the pandemic, the UK was opening clinical trials in a matter of a few weeks. But before it used to take years to complete a clinical trial. What changed?
It was really fascinating, because for many years, we believed that research is inherently slow. It used to take 20 years to get a drug to market. Most cancer patients, unfortunately, will succumb by the time a drug gets to market. We showed the world that it could be done in a year if you modernize your process, run parts of the process in parallel, and use digital tools.
Of course, opening a clinical trial during a pandemic is not necessarily the same as a clinical trial for cancer. But you had a breakthrough moment for the cancer vaccine project at an early stage.
There was a trial run by BioNTech, called BNT122, on people with high-risk bowel cancer, which was not recruiting very well across the world. So when we announced the Cancer Vaccine Launch Pad, the UK cancer community took that opportunity. We opened that trial at Birmingham University Hospital, which was the most surprising thing for me, because it is not a leading cancer vaccine studies center.
We needed to get 10,000 patients enrolled in the trial, and we got there within the course of three months. It was quite amazing. It just goes to show that because we're a single health care system, we can do this much quicker than any other country.
The dominoes started falling very quickly on the back of that success: we opened a head and neck cancer trial in Liverpool, an esophageal and gastric cancer trial in Dundee, and a lung cancer trial in London. We started to create a community of people who were all pushing for launching cancer vaccine trials as quickly as possible.
Several mRNA-based cancer vaccines are in late-stage clinical trials internationally, and the UK is currently running 15 cancer-vaccine trials. When will we see the first approved mRNA cancer vaccine?
We have a trial to stop skin cancer coming back after you cut it out. It's now completed. We over-recruited again, just like every single one of the trials that we ran, and the trial finished one year ahead of schedule. That's completely unheard of in cancer trials because they normally run over-long.
What will happen now is that, over the next six to 12 months, we will monitor the people in the trial and work out if there's a difference between the people who took the cancer vaccine and the ones who didn't. We're hoping to have results by the end of the year or beginning of 2026. If it's successful, we will have invented the first approved personalized mRNA vaccine, within only five years of the first licensed mRNA vaccine for Covid. That's pretty impressive.
Hear Lennard Lee speak at WIRED Health on March 18 at Kings Place, London. Get tickets at health.wired.com .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
6 hours ago
- The Hill
School struggle to solve chronic absenteeism problem since pandemic
Schools are struggling to get chronic absenteeism to pre-pandemic levels, five years after it spiked during COVID-19. Chronic absenteeism is defined as missing more than 10 percent of school days. Pockets of hope can be seen around the country, as some school districts have managed to get a handle on it. But experts say it could still be a long road until national success is achieved. During the height of the pandemic, national chronic absenteeism rates jumped to almost 30 percent from 15 percent, according to Attendance Works. Since then, chronic absenteeism has slowly declined but remains far from pre-pandemic levels. While data is still emerging from the 2024-2025 school year, the 2023-2024 academic year saw chronic absenteeism rates of around 25 percent. 'I believe that states and schools and school district leaders are working very hard to curb their attendance rates, and I believe that it takes a lot longer to address some of these things. But that doesn't mean that we should throw in the towel,' said Carl Felton, policy analyst on the P-12 team at EdTrust. 'I think that we have to continue to be consistent about setting clear attendance definitions, be consistent about supporting schools and leaders to make sure that they have the resources and strategic partnerships to support them with addressing chronic absenteeism,' he added. High rates of chronic absenteeism lead to poor academic and social outcomes, along with financial consequences for some schools. Attendance Works, a leading nonprofit aiming to fix chronic absenteeism, released a report showing the increase in data collection and transparency among states on this issue in recent years. It found 21 states have set tangible goals for their fight to keep kids in the classroom. Hedy Chang, founder and executive director of Attendance Works, pointed to multiple reasons chronic absenteeism becomes an issue, such student aversion to attending because of problems like bad grades, teenagers not engaged with the lesson plans or other students in meaningful ways, barriers like illness or home problems and misconceptions about missing school. It is important, Chang notes, for schools to address issues at the beginning of the academic year to 'help kids feel connected, help them feel engaged, make sure that there isn't anything pushing them out of school and create positive school climates.' 'It also makes kids and families more willing to share when they're experiencing a barrier so they can get resources to address it and makes them more likely to trust school staff when they're sharing information,' she added. Strategies deployed throughout the country have included better messaging systems to parents and students, changes in curriculum to keep students more engaged and overcoming barriers such as better access to transportation to school. Forty percent of school leaders put combatting chronic absenteeism into their top three most pressing issues for the last school year, according to RAND, a research nonprofit. The issue has persisted, especially in urban areas, which RAND found were five to six times more likely to see extreme chronic absenteeism rates. And one of the difficulties addressing the issues is some parents and students do not see the problem with it. RAND found one-quarter of students do not see chronic absenteeism as a big deal. 'The other thing that they're doing is tailoring approaches by the age group of students. So, districts are saying for younger students, the key here is about building habits for students and families, to build up feelings about the importance of being in person at school,' said Melissa Diliberti, lead author of the RAND survey. 'And then, as students get older, districts are kind of switching away to focusing […] more on engagement,' she added. 'One of the reasons that older kids might be less likely or more likely to miss school is that they don't feel as engaged at school.' While the situation seems dire, most experts said they believe schools will be able to recover to their pre-pandemic levels, albeit slowly. Attendance Works propped up Virginia and Colorado as two states that have successfully worked to combat chronic absenteeism. Virginia's chronic absenteeism rate rose to 20 percent during the height of the pandemic but is already down to 15 percent, pointing to local collaboration with everyone from bus drivers to principals, investments in tutoring and reading, and creating new messaging systems for parents and students regarding absences. Schools have 'to keep pushing through' and 'get more intentional and strategic,' Chang said. 'But the fact that you aren't quite seeing as quick reductions as you might have in the beginning shouldn't be a sign … don't feel discouraged about that, feel motivated about it, because it's a call that we have to do even deeper problem solving,' she added.
Boston Globe
9 hours ago
- Boston Globe
‘Is it the dying kind?'
Still, O must have sensed something was wrong. Usually calm and even-keeled, O started having sudden bursts of frenzy. His teacher, aware of my diagnosis, wasn't surprised to hear about his new behavior at home. She gently suggested that honesty — framed in a way he could understand — might help ease his anxiety. Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up Maybe the teacher was right, but how the hell do I do that? O loves Band-Aids — maybe I could start there. He was thrilled when I showed him the ones from my chemo shots and IVs — even more so when I brought a few special ones home just for him. On the days I was pumped so full of steroids I thought I might molt, we turned the jittery energy into epic Nerf baseball games in the living room. Now that I had begun letting him into the story, O's anxious edge faded, and he settled back into himself. That gave me the courage — if you can call it that — to finally say the dreaded c-word. I slipped it into the middle of a game of Sorry! like it was just another move. I'm not sure exactly how I said it. I was nervous — the only time I'd ever felt that way talking to O — and the words came out awkwardly. I do remember that what I said didn't seem to register. 'Cancer' meant nothing to him. Mine was his first. I wondered how much of my circumstances he was absorbing. Life, at least for him, seemed to have returned to normal. Then, one night while I was tucking him in, O, who was a master at avoiding uncomfortable conversations, surprised me by asking, 'Why do you go to so many doctors now?' We talked about how, even though I looked and felt mostly fine, my body couldn't fight off bugs as well as his and that I needed a lot of doctor visits to help me get better. I asked what he thought about wearing a mask at school, especially during sick season. My shy, COVID-era kiddo — who already had used a mask as a shield — started wearing one again without hesitation. That only made me feel worse. O rarely mentioned my illness, but then one day, he told my wife about the special breakfast he was planning to make me when I was 'all done with chemo.' She softly clarified that I might never be off chemo, even if the doses get lower. 'Why?' O asked. 'To keep the cancer levels down.' 'Papa has cancer?' 'Yes, of course. You knew that.' For a moment, he said nothing. Then his face brightened with a smile feigning revelation. 'Oh yeah.' 'Do you remember what it's called?' 'Muh-muh something.' 'Multiple myeloma.' A long pause. 'Is it the dying kind of cancer?' Somewhere along the way, O had learned that cancer could mean dying. We had never talked about that part. Another longer pause. My wife, not knowing how to respond, said, 'Well, the medicine Papa's getting is working really well.' He said nothing, and for the rest of the evening he played with unusual intensity, forcing laughter — the kind that seemed meant to drown out whatever else was there. I wondered if the perfect book could help. O treasures his books. But none of the ones I could find about illness felt right. If anything, I feared they'd make him feel worse. So, in a burst of steroid-fueled arrogance, I decided to write one myself, a story where the father actually said all the right things. I rewrote obsessively, dreaming about blue whales (O loves whales) in New York City subways. Finally, I landed on a story I believed would work for him. But the magic for O was in a physical book itself — choosing one from the library, getting lost in the illustrations, finding the perfect spot for it on his shelf. I later learned, though, that it might be a year or two before the book I was writing would be published. By then, O might not even care about whales. Then again, what if O was actually doing fine? Aren't kids supposed to be resilient? Yes, he now wore a mask to school, and we couldn't go on our beloved weekend subway adventures anymore. And I could no longer be his sick buddy when he was having tough nights. But he adjusted so quickly — maybe he just thought this was normal now that he was 6. Recently, O revealed that he'd been concocting a grand imaginary scheme to trap his mom. It started with a birdcage and escalated into locking her at the top of a tall tower with no door and no stairs. Then he decided he'd give her medicine to 'make her a little sick' and might need to build a coffin in case something went wrong. 'I am not sure I like this game,' my wife said. O, who'd presented his plan with good humor and without a hint of malice, said, 'I already made a plan in my calendar.' Maybe I should hold off on reading more Brothers Grimm to him, but I suspect it's his way of working through some complex feelings. On my next designated steroid day, I started writing a new book for O based on his wild scheme. If he could go into an imaginary world to control sickness and death, so could I. Through this circus of Nerf baseball and Band-Aids and tales of whales and birdcages, I had been so focused on how I would tell O that I had lost sight of what I was actually trying to say. I wrote this piece to try and figure it out. If this were an after-school special, I'd probably realize that all I really wanted to tell him was that I love him and I just had to find the right way to do it. Or that I had more to learn from him than he did from me. That is not where this landed, though. I finally know what I've been trying to say all along, but how the hell do I tell him I'm sorry?
Los Angeles Times
15 hours ago
- Los Angeles Times
COVID surges nationwide with highest rates in Southwest as students return to school
COVID-19 rates in the Southwestern United States reached 12.5% — the highest in the nation — according to new data from the U.S. Centers for Disease Control and Prevention released this week. Meanwhile, Los Angeles County recorded the highest COVID levels in its wastewater since February. The spike, thanks to the new highly contagious 'Stratus' variant, comes as students across California return to the classroom, now without a CDC recommendation that they receive updated COVID shots. That change in policy, pushed by Health and Human Services Secretary Robert F. Kennedy Jr., has been criticized by many public health experts. The COVID-19 virus, SARS-CoV-2, mutates often, learning to better transmit itself from person to person and evade immunity created by vaccinations and previous infections. The Stratus variant, first detected in Asia in January, reached the U.S. in March and became the predominant strain by the end of June. It now accounts for two-thirds of virus variants detected in wastewater in the U.S., according to the CDC. The nationwide COVID positivity rate hit 9% in early August, surpassing the January post-holiday surge, but still below last August's spike to 18%. Weekly deaths, a metric that lags behind positivity rates, has so far remained low. In May, RFK Jr. announced the CDC had removed the COVID vaccine from its recommended immunization schedule for healthy children and healthy pregnant women. The secretary argued it was the right move to reverse the Biden administration's policy, which in 2024, 'urged healthy children to get yet another COVID shot, despite the lack of any clinical data to support the repeat booster strategy in children.' That statement promptly spurred a lawsuit from a group of leading medical organizations — including the American Academy of Pediatrics, the American College of Physicians and the American Public Health Association — which argued the 'baseless and uninformed' decision violated federal law by failing to ground the policy on the recommendation of the scientific committee that looks at immunization practices in the U.S. The Advisory Committee on Immunization Practices has been routinely recommending updated COVID vaccinations alongside the typical yearly flu vaccination schedule. In its update for the fall 2024-spring 2025 season, it noted that in the previous year, a COVID booster decreased the risk of hospitalization by 44% and death by 23%. The panel argued the benefit outweighed isolated cases of heart conditions and allergic reactions associated with the vaccine. The panel also acknowledged that booster effectiveness decreases as new COVID strains — for which the boosters were not designed — emerge. Nevertheless, it still felt that most Americans should get booster shots. The CDC estimates that only about 23% of adults and 13% of children received the 2024-2025 COVID booster — even with the vaccine recommendation still in place. That's compared to roughly half of adults and children who received the updated flu shot in the same time frame.
